BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8640819)

  • 1. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.
    Gupta E; Safa AR; Wang X; Ratain MJ
    Cancer Res; 1996 Mar; 56(6):1309-14. PubMed ID: 8640819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
    Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
    J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats.
    Bansal T; Mishra G; Jaggi M; Khar RK; Talegaonkar S
    Eur J Pharm Sci; 2009 Mar; 36(4-5):580-90. PubMed ID: 19135530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
    Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
    Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital.
    Gupta E; Wang X; Ramirez J; Ratain MJ
    Cancer Chemother Pharmacol; 1997; 39(5):440-4. PubMed ID: 9054958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
    Iyer L; Ramírez J; Shepard DR; Bingham CM; Hossfeld DK; Ratain MJ; Mayer U
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):336-41. PubMed ID: 11914914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.
    Sugiyama Y; Kato Y; Chu X
    Cancer Chemother Pharmacol; 1998; 42 Suppl():S44-9. PubMed ID: 9750028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
    Klein CE; Gupta E; Reid JM; Atherton PJ; Sloan JA; Pitot HC; Ratain MJ; Kastrissios H
    Clin Pharmacol Ther; 2002 Dec; 72(6):638-47. PubMed ID: 12496745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein.
    Bansal T; Awasthi A; Jaggi M; Khar RK; Talegaonkar S
    Life Sci; 2008 Aug; 83(7-8):250-9. PubMed ID: 18619980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
    Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
    Clin Pharmacol Ther; 2002 Sep; 72(3):265-75. PubMed ID: 12235447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.
    Tobin PJ; Hong Y; Seale JP; Rivory LP; McLachlan AJ
    J Pharm Pharmacol; 2005 Jan; 57(1):39-45. PubMed ID: 15638991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biliary excretion of irinotecan and its metabolites.
    Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
    J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain.
    de Jong FA; Kitzen JJ; de Bruijn P; Verweij J; Loos WJ
    Cancer Biol Ther; 2006 Sep; 5(9):1105-10. PubMed ID: 16969123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of cyclosporin A on the pharmacokinetics and toxicities of irinotecan mediated by UGT1A1
    Qin Y; Wang N; Chen F; Han X; Zhu Y; Rang Y; Zhai X; Lu Y
    Pharmazie; 2020 May; 75(5):186-190. PubMed ID: 32393425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G].
    Valenzuela Jiménez B; González Sales M; Escudero Ortiz V; Martínez Navarro E; Pérez Ruixo C; Rebollo Liceaga J; González Manzano R; Pérez Ruixo JJ
    Farm Hosp; 2013; 37(2):111-27. PubMed ID: 23789755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan (CPT-11) metabolism and disposition in cancer patients.
    Sparreboom A; de Jonge MJ; de Bruijn P; Brouwer E; Nooter K; Loos WJ; van Alphen RJ; Mathijssen RH; Stoter G; Verweij J
    Clin Cancer Res; 1998 Nov; 4(11):2747-54. PubMed ID: 9829738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.
    Berg AK; Buckner JC; Galanis E; Jaeckle KA; Ames MM; Reid JM
    J Clin Pharmacol; 2015 Nov; 55(11):1303-12. PubMed ID: 25975718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats.
    Chu XY; Kato Y; Sugiyama Y
    Drug Metab Dispos; 1999 Apr; 27(4):440-1. PubMed ID: 10101137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38.
    Lin LC; Wang MN; Tsai TH
    Chem Biol Interact; 2008 Aug; 174(3):177-82. PubMed ID: 18579105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
    Yamamoto W; Verweij J; de Bruijn P; de Jonge MJ; Takano H; Nishiyama M; Kurihara M; Sparreboom A
    Anticancer Drugs; 2001 Jun; 12(5):419-32. PubMed ID: 11395570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.